Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study
Last Updated: Tuesday, March 17, 2020
Long-term follow-up from the phase 3 RESPONSE study further demonstrated the efficacy and safety of ruxolitinib, versus best available therapy, for patients with hydroxyurea-intolerant/resistant polycythemia vera, with 55% probability of maintaining complete hematological remission at 5 years (95% CI 32-73).
Advertisement
News & Literature Highlights
